drugset / Trial / NCT01837927

Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.

NCT01837927

Phase 3 Withdrawn Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will assess the Efficacy of NVA237 (50 μg o.d) using tiotropium (5μg μg o.d) as active control in COPD patients.

Timeline

Start
2014-04
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrrolate Small molecule 50 ug Inhaled
Comparator Tiotropium Other / unclassified 5 ug Inhaled